Background: Cyclins and their catalytic partners, the cyclin-dependent kinases (Cdks), function as key regulators of the eukaryotic cell cycle. Specific cyclin-Cdk complexes are active at successive stages during the cell cycle and control cell-cycle progression by phosphorylating specific target proteins, most of which have not yet been identified. B-Myb, a conserved member of the Myb oncoprotein family, is a sequence-specific DNA-binding protein expressed in virtually all proliferating mammalian cells. Increasing evidence suggests that BMyb plays an important role during the late G1 and early S phases of the cell cycle. In this study, we have examined the regulation of B-Myb activity by cyclin-Cdks. 
Background
In recent years, the cyclins and their catalytic partners, the cyclin-dependent kinases (Cdks), have been identified as key regulators of the eukaryotic cell cycle (see [1] , and references therein). It is generally accepted that different cyclin-Cdk complexes appear at different times during the cell cycle and control cell-cycle progression by phosphorylating specific target proteins. In particular, complexes of cyclin D1 with Cdk4 or Cdk6 have been shown to play an important role at the 'restriction point' in the G1 phase of the cell cycle at which cells become committed to the next mitotic cycle, whereas cyclin E-Cdk2 complexes are most critical for the transition from G1 to S phase and cyclin A-Cdk2 complexes are required during S phase [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Although certain cyclin-Cdk target proteins, such as the retinoblastoma protein [13] , have been studied in great detail, many targets, particularly those regulated by the kinases associated with cyclins A and E, remain to be identified.
B-myb is a member of the myb proto-oncogene family that is conserved among vertebrates [14] [15] [16] [17] . The B-Myb protein is a sequence-specific DNA-binding protein which differs from other members of the Myb family (c-Myb and A-Myb) in that it has extremely weak or undetectable transactivation activity [14] [15] [16] [17] [18] [19] . This lack of transactivation activity was initially taken to mean that B-Myb acts as an inhibitor of other members of the Myb family [16, 19] . Increasing evidence now suggests that B-Myb plays a general role during cellcycle progression in most, if not all, cell types.
In contrast to c-myb and A-myb, the functions of which appear to be restricted to specific cell types, B-myb is expressed in virtually all proliferating cells and tissues [14] [15] [16] [17] 20, 21] . During embryonic development of the mouse, the expression of B-myb is tightly linked to the proliferative activity of cells and tissues [21] . B-myb expression is controlled by the transcription factor E2F, and expression reaches its maximum at the G1-S-phase boundary and is maintained at this high level during S phase of the cell cycle [22, 23] . Overexpression of B-myb can allow cells to escape the cell-cycle arrest that is induced by overexpression of the oncoprotein p53 and mediated by the Waf1/Cip1 protein [24] . Interestingly, this effect of B-myb does not involve restoration of p53-dependent inhibition of cyclin E-Cdk2 kinase activity, raising the possibility that B-myb acts at a later stage than cyclin E-Cdk2 during cell-cycle progression.
Here, we have examined the regulation of B-Myb activity by a number of components of the cell-cycle machinery. We show that the transactivation potential of B-Myb is repressed by a regulatory domain located at the carboxyl terminus of the protein and that the inhibitory effect of this domain is relieved by phosphorylation of B-Myb induced by cyclin A-Cdk2. Our studies therefore identify B-Myb as a target for cyclin A-Cdk2 kinase activity and indicate that B-Myb activity is regulated by phosphorylation. Furthermore, our work provides evidence for a link between the Myb family and the cyclins and Cdks which constitute the cell-cycle machinery.
Results

A cyclin-dependent inhibitory domain at the carboxyl terminus of B-Myb
The carboxy-terminal domain of c-Myb has previously been implicated in repressing the activity of the c-Myb protein [25] [26] [27] . To investigate whether the apparent lack of transactivation activity of B-Myb is due to inhibition mediated by the protein's carboxyl terminus, we first assessed the transactivation potential of carboxy-terminally deleted B-Myb. Consistent with previous studies [16, 19] , full-length B-Myb was virtually inactive, whereas truncated B-Myb (B-Myb-⌬3) activated a Myb-responsive reporter gene containing the herpes simplex virus thymidine kinase promoter fused to three Myb-binding sites (Fig. 1) . Further deletion of an acidic region located in the center of B-Myb produced an inactive protein (B-Myb-⌬Pvu). These results suggested that the transactivation activity of B-Myb is repressed by an inhibitory domain located at the carboxyl terminus of the protein.
To confirm this result in a different promoter context, we examined the transactivation potential of GAL4-B-Myb fusion proteins; these proteins consisted of B-Myb either including its carboxy-terminal domain (GAL4-B-Myb-fl) or lacking this domain (GAL4-B-Myb-⌬3), fused to the DNA-binding domain of the yeast GAL4 protein. We used the adenovirus E4 promoter fused to five copies of the GAL4-binding site as the GAL4-responsive test promoter driving reporter gene expression. In accordance with the results in Figure 1a ,b, the truncated fusion protein activated a GAL4-dependent reporter gene, whereas the fulllength fusion protein was virtually inactive, confirming the existence of an inhibitory domain at the carboxyl terminus of B-Myb (Fig. 1c) . (Fig. 1f) , consistent with the idea that cyclin A counteracts the inhibitory effect of the carboxy-terminal domain.
Cyclin-dependent regulation of B-Myb activity does not require the B-Myb DNA-binding domain
To confirm the specificity of the cyclin A-dependent increase in transactivation by B-Myb, we examined the effect of cyclin A coexpression on the activity of a GAL4-BMyb fusion protein, using a GAL4-dependent reporter gene to monitor transactivation. This fusion protein, which has a deletion of the Myb DNA-binding domain and therefore lacks Myb-specific DNA-binding activity, was also strongly stimulated by cyclin A (Fig. 2) . As a control, we performed a similar experiment using a GAL4-Myc fusion protein, to provide a completely different GAL4-dependent transactivator; the activity of the GAL4-Myc protein was not affected by cyclin A coexpression (Fig. 2 ). This experiment therefore shows that the effect of cyclin A on B-Myb is specific and is not dependent on a particular reporter gene assay system. Furthermore, because this experiment used a fusion protein that had the GAL4 DNA-binding domain in place of the B-Myb DNA-binding domain, it shows that cyclin A does not act by simply increasing the binding of BMyb to Myb-binding sites.
Cyclin A coexpression induces a slow-migrating phosphorylated form of B-Myb
The stimulatory effect of coexpressed cyclin A on B-Myb activity raised the possibility that B-Myb might be phosphorylated by a cyclin A-Cdk complex. To address this possibility, B-Myb was coexpressed with different cyclins and the mobility of the B-Myb protein was analyzed by SDS gel electrophoresis and western immunoblotting. Figure 3a shows that a slow-migrating form of B-Myb was induced by coexpression of cyclin A but not by coexpression of other cyclins. Immunoprecipitation of cyclin-Cdk complexes from the transfected cells, followed by in vitro kinase assays using the synthetic peptide KIRSPRRFIGSPRTPVSPVK (single letter amino-acid code) as a model substrate, showed that kinase activity was indeed induced by expression of the different cyclins (data not shown). The inability of cyclins D1 and E to induce a slow-migrating form of B-Myb is therefore not because these cyclins lack associated kinase activity but instead reflects a specific interaction of cyclin A-Cdk2 with B-Myb. Cyclin A did not affect the mobility of carboxyterminally truncated B-Myb or of c-Myb (Figs. 3b,c) , confirming that this mobility effect of cyclin A is specific for full-length B-Myb.
During S phase of the cell cycle, the naturally active kinase partner of cyclin A is Cdk2 [3, 5, 7, 8] . To assess whether the endogenous Cdk2 present in the transfected cells was involved in the effect of cyclin A on B-Myb, we coexpressed B-Myb and cyclin A with increasing amounts of a kinase-negative mutant form of Cdk2, referred to as Cdk2-R33 (U. Deuschle and S.F., unpublished observations). We observed that Cdk2-R33 suppressed the appearance of the slow-migrating form of B-Myb, probably by titrating out the cyclin that would otherwise bind to endogenous wild-type kinase (Fig. 3d) . This is consistent with the idea that the cyclin A-Cdk2 complex is responsible for the phosphorylation of B-Myb. To examine further whether the change in the electrophoretic mobility of BMyb induced by cyclin A was caused by phosphorylation, we performed an in vitro phosphatase treatment experiment. As shown in Figure 3e , treatment with potato acid phosphatase (PAP) converted the retarded form of B-Myb into a faster migrating form, confirming that the cyclin Amediated effect observed on the pattern of electrophoretic mobility of B-Myb was due to phosphorylation.
To demonstrate the phosphorylation of B-Myb directly, BMyb was coexpressed with cyclin A, labeled with 32 Porthophosphate in vivo and immunoprecipitated. As shown in Figure 4a Aliquots of the immunoprecipitate were treated with potato acid phosphatase (PAP) as described [38] , and analyzed by SDS-PAGE and autoradiography. Control incubations using phosphatase inactivated by treatment with sodium orthovanadate and ␤ glycerol phosphate or by heat did not lead to a change of the electrophoretic mobility pattern of B-Myb (data not shown).
Figure 4
Cyclin A-dependent phosphorylation of B-Myb. COS-7 cells cotransfected with an expression vector encoding full-length B-Myb (5 g), with or without a cyclin A expression vector (3 g), were labeled with 32 P-orthophosphate. Cell extracts were analyzed by immunoprecipitation (IP) with antibodies specific for B-Myb, followed by SDS-PAGE and autoradiography. The amounts of immunoprecipitate loaded onto the gel (a) were adjusted such that equal amounts of BMyb protein were present, as assessed by western blot (b). In order to examine whether B-Myb is a direct target of cyclin A-Cdk2, we expressed the carboxy-terminal half of B-Myb as a bacterial glutathione S-transferase fusion protein, subjected it to kinase reactions in vitro using immunopurified cyclin A-Cdk2, and compared it by twodimensional tryptic phosphopeptide analysis with B-Myb phosphorylated in vivo. As illustrated in Figure 5c , bacterial B-Myb could be phosphorylated in vitro using immunopurified cyclin A-Cdk2 and yielded a number of tryptic phosphopeptides, the most prominent of which comigrated with peptides obtained from B-Myb labeled in vivo (Fig.  5b ). Note that a low level of phosphorylation of B-Myb also occurred in the absence of cotransfected cyclin A (Fig. 5a ): we attribute these phosphorylations to the presence of endogenous cyclin A-Cdk2 in the transfected cells. This interpretation is supported by the finding that this basal level of phosphorylation could be decreased by cotransfection of a dominant-negative mutant of Cdk2 (data not shown). Taken together, the results presented in Figures 4 and 5 show that cyclin A strongly induces the phosphorylation of B-Myb at a number of sites, at least some of which are also phosphorylated by cyclin A-Cdk2 in vitro. We conclude that B-Myb is a direct target for cyclin A-Cdk2.
Phosphorylated B-Myb is present during S phase
We next investigated whether phosphorylation of B-Myb also occurs in nontransfected cells. Swiss 3T3 fibroblasts were synchronized by serum starvation, labeled with 32 Porthophosphate and their proteins used for immunoprecipitation experiments. A phosphorylated form of B-Myb that had the same electrophoretic mobility as the slow-migrating form of the protein induced by coexpression with cyclin A could be specifically immunoprecipitated with anti-B-Myb antiserum from S-phase cells, but not from growth-arrested cells (data not shown). A similar form of endogenous B-Myb that was sensitive to phosphatase treatment has also been described in a recent report [28] ; our data directly demonstrate the phosphorylation of endogenous B-Myb (by phosphate labeling) and thus confirm and extend these results. To demonstrate that endogenous B-Myb is phosphorylated at the same sites as those phosphorylated in the presence of coexpressed cyclin A, we performed two-dimensional tryptic phosphopeptide mapping of endogenous B-Myb isolated from 32 Porthophosphate-labeled Swiss 3T3 fibroblasts (Fig. 5d) .
We observed a pattern of phosphopeptides similar to the pattern obtained from ectopically expressed B-Myb (compare Figs. 5d and 5b) . Although the relative intensities of some of the phosphopeptide spots varied between the two proteins, the fact that most of the phosphopeptides comigrated indicates that the slow-migrating form of B-Myb induced by coexpression of cyclin A is phosphorylated at similar sites as endogenous B-Myb.
Discussion
Our results provide evidence that B-Myb, a conserved member of the Myb transcription factor family, is regulated directly by the cell-cycle machinery, and lead to a major revision of the current view of B-Myb function.
Although previous work has suggested that B-Myb is an inhibitory member of the Myb family [16, 19] , we have now shown that B-Myb is a transactivating factor that is regulated by its carboxy-terminal domain in a cell-cycledependent manner.
Our findings highlight the central role of the carboxyterminal domain in the regulation of B-Myb activity. We have shown that the inhibitory function of the carboxyl terminus is counteracted by phosphorylation mediated by cyclin A-Cdk2, suggesting that the carboxyl terminus of B-Myb acts as a cell-cycle sensor. We have not yet addressed in detail the mechanism by which the phosphorylation of B-Myb affects its transactivation activity. It is clear, however, that the DNA-binding domain of B-Myb is not required for cyclin-dependent regulation and, hence, that phosphorylation does not simply regulate the DNAbinding activity of the protein.
A second finding from our work is the identification of BMyb as a target for phosphorylation by cyclin A-Cdk2. We have shown that the inhibition of B-Myb transactivation activity by the carboxyl terminus is relieved specifically by the action of cyclin A-Cdk2 and is accompanied by phosphorylation at multiple sites of the protein. Some of these sites were also phosphorylated by cyclin A-Cdk2 in vitro, suggesting that B-Myb is a direct substrate for the kinase. At present, we do not know whether all of the sites that showed cyclin A-induced phosphorylation are directly phosphorylated by cyclin A-Cdk2. It is possible that, in addition to direct phosphorylation by cyclin A-Cdk2, other kinases acting on B-Myb are activated by cyclin A-Cdk2, or that the initial phosphorylation of B-Myb by cyclin A-Cdk2 alters the conformation of the B-Myb protein in such a way that it becomes accessible to other kinases. Nevertheless, a number of the phosphorylation sites induced by cyclin A-Cdk2 are clearly recognized by immunopurified cyclin A-Cdk2 in vitro, suggesting that these sites are phosphorylated directly by cyclin A-Cdk2.
B-myb expression is regulated by the E2F transcription factor and reaches maximum levels during the late G1 and early S phases of the cell cycle [22, 23] , a time at which cyclin A-Cdk2 becomes active as a kinase [3, 5, 7, 8] . The role of cyclin A-Cdk2 during S phase is as yet poorly understood. Cyclin A-Cdk2 has been shown to phosphorylate certain members of the E2F-DP transcription factor family, thereby causing inhibition of their DNA-binding activity during S phase [29] [30] [31] . By contrast to the inhibition of E2F-DP, we show here that the transactivation potential of B-Myb is increased by cyclin A-Cdk2. Our results therefore provide evidence for a positive role of cyclin A-Cdk2 and imply that B-Myb is a cell-cycle-regulated transcription factor activated at the onset of S phase. The relevance of BMyb in cell proliferation is supported by the observation that it is expressed in virtually all proliferating mammalian cells [14] [15] [16] [17] 20, 21] , and that B-myb antisense oligonucleotides inhibit cell proliferation [32, 33] . Thus, B-Myb appears to be an essential component of the machinery which both controls transition from G1 to S phase and is regulated by cyclin A-Cdk2. Further analysis of this machinery, in particular the identification of the genes that are themselves regulated by B-Myb, might provide interesting insights into the role of cyclin A-Cdk2 during S phase.
While this work was in progress, Sala et al. [34] have shown that the transactivation potential of human B-Myb is also increased upon coexpression of cyclins, in accordance with the results described here.
Conclusions
Cyclin A-Cdk2 is required during S phase of the cell cycle. However, with the exception of the transcription factor E2F, the activity of which is inhibited by cyclin A-Cdk2-mediated phosphorylation, convincing protein targets for cyclin A-Cdk2 have yet to be identified. It is therefore not clear whether cyclin A-Cdk2 has other roles during S phase, in addition to inhibiting E2F. The work presented here leads to two major conclusions. First, it identifies B-Myb, a highly conserved member of the Myb oncoprotein family, as a target for cyclin A-Cdk2. Cyclin A-Cdk2-mediated phosphorylation counteracts the effects of an inhibitory domain located at the carboxyl terminus of B-Myb and thereby increases the transactivation potential of B-Myb. Our results, therefore, provide evidence for a positive role of cyclin A-Cdk2. Second, our studies also shed new light on the function of B-Myb. Although previous work has suggested that B-Myb is an inhibitory member of the Myb family, it now appears that B-Myb is a transactivating factor that is regulated by phosphorylation of its carboxyterminal domain in a cell-cycle-dependent manner.
Materials and methods
Expression vectors and transient transfection assays
Expression vectors for full-length mouse B-myb and GAL4-B-myb have been described [20] . The vector encoding GAL4-B-Myb carries a deletion of the B-myb coding region between an AgeI and a HincII site; the deleted sequences encode the DNA-binding domain of B-Myb. Expression vectors for B-Myb-⌬3, GAL4-B-Myb-⌬3 and BMyb-⌬Pvu were generated by 3′ truncation of the B-Myb coding region at ScaI (⌬3 truncations) or PvuII (⌬Pvu truncation) sites. The c-myb expression vector was obtained by cloning the complete coding region of mouse c-myb into pCDNA3 (Invitrogen). Expression vectors for human cyclins A, D1 and E were obtained from R. Weinberg. A kinase-negative mutant of Cdk2, Cdk2-R33, which has Lys33 mutated to arginine, was obtained from U. Deuschle and subcloned into pCDNA3. The expression vector encoding the GAL4 DNAbinding domain fused to the amino-terminal half of v-Myc, pGAL4-Myc(Not), has been described [35] . COS-7 cells were transfected as described [20] . The amounts of expression vectors given in the figure legends were used for single 10 cm tissue culture dishes. Transactivation activities were determined by transfecting each plate with 5 g of the Myb-responsive luciferase reporter gene p3xATk-Luc [36] or the GAL4-responsive plasmid pG5E4-38Luc [20] . To correct for differences in transfection efficiency, plates were cotransfected with 0.5 g of the ␤-galactosidase reporter gene pCMV␤ (Clontech). Luciferase and ␤-galactosidase activities were determined as described [20] .
Western blotting, in vivo labeling and immunoprecipitations
B-Myb was detected by western blotting as described [20] . For phosphate labeling, cells were pre-incubated in phosphate-free medium (DMEM; ICN) for 30 min and then incubated with 32 Porthophosphate (Amersham, carrier free) in phosphate-free medium at 100-400 mCi ml -1 for 5 h. For labeling with radioactive methionine, the cells were incubated with 35 S-methionine (Amersham; > 800 Ci mmol -1 ) in methionine-free medium at 100 mCi ml -1 for 3 h. Cells were washed with phosphate-buffered saline (PBS) and lysed in 1-2 ml lysis buffer (10 mM Tris-HCl, pH 7.8; 50 mM NaCl; 0.5% NP40; 0.5% sodium deoxycholate; 0.1% SDS) per 10 cm tissue culture plate. For phosphate-labeled cells, the lysis buffer was supplemented with 1 mM NaF and 0.5 mM sodium vanadate. The lysate was sheared with a syringe, clarified and immunoprecipitated with serum raised against the carboxyl terminus of mouse B-Myb [28] or with preimmune serum. Precipitates were collected using Staphylococcus aureus (Pansorbin, Calbiochem) and washed three times with lysis buffer. After boiling in 50 l SDS sample buffer, the samples were diluted into 1 ml lysis buffer, clarified and immunoprecipitated again, this time using B-Myb serum raised against the DNA-binding domain of mouse B-Myb [20] , in order to reduce the background. Precipitates were processed as described above and analyzed by 6% SDS-PAGE and autoradiography. Transfected COS-7 cells were labeled and immunoprecipitated as described above, except that only one immunoprecipitation step (using antiserum against the B-Myb DNAbinding domain) was performed.
Cell-cycle analysis
Swiss 3T3 cells were synchronized as described [37] . Synchronization was verified by labeling the cells for 15 min with 5 mCi ml -1 3 H-thymidine (Amersham; 83 Ci mmol -1 ), followed by precipitation with 10% trichloroacetic acid and counting of the incorporated radioactivity in a liquid scintillation counter. Additionally, B-myb expression was analyzed by northern blotting, as described [21] .
In vitro kinase reaction
Human 293 cells overexpressing human cyclin A and Cdk2 were lysed as described [37] and extracts immunoprecipitated using either antiCdk2 or anti-cyclin A antibodies (Santa Cruz). Immunoprecipitates were used to phosphorylate 5 g bacterially expressed GST-B-Myb (residues 227-704) as described [36] .
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